LGALS3 and type 2 diabetes mellitus: Another glycomimetic Gal-3 inhibitor (Salameh et al., 2010), Cpd47, blocked Gal-3 inhibition of insulin-stimulated glucose transport in L6 myocytes and has also been tested in Type 2 diabetes models in vivo.